Background. Although short-term graft survival has improved substantially in renal transplant recipients, longterm graft survival has not improved over the last decades. The lack of knowledge of specific causes and risk factors has hampered improvements in long-term allograft survival. There is an uncertainty if inflammation is associated with late graft loss. Methods. We examined, in a large prospective trial, the inflammation markers high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) and their association with chronic graft dysfunction. We collected data from the Assessment of Lescol in Renal Transplant trial, which recruited 2102 maintenance renal transplant recipients. Results. Baseline values were hsCRP 3.8 6 6.7 mg/L and IL-6 2.9 6 1.9 pg/mL. Adjusted for traditional risk factors, hsCRP and IL-6 were independently associated with death-censored graft loss, the composite end points graft loss or death and doubling of serum creatinine, graft loss or death. Conclusion. The inflammation markers hsCRP and IL-6 are associated with long-term graft outcomes in renal transplant recipients.
Introduction
Advances in immunosuppression, histocompatibility testing, surgery and medical management have allowed transplantation to become the favoured treatment for patients with end-stage renal disease, with a low rate of acute rejection and excellent short-term results. The paradox is that longterm graft survival has barely improved over the last two decades despite short-term improvements in graft survival [1] . Annual graft loss is still 2-7% [2] [3] [4] and the average deceased donor kidney transplant functions for~10 years [5] . Clinically, we observe a progressive transplant dysfunction characterized by a slowly rising serum creatinine, proteinuria and hypertension [3] . Early detection of chronic transplant dysfunction is recognized to be important, although current interventions have a limited effect (e.g. 'creeping creatinine study'). Current recommendations are to follow serum creatinine, estimated glomerular filtration rate, proteinuria and to consider performance of protocol (surveillance) biopsies or to have a low threshold for early diagnostic biopsy [4] . Once serum creatinine rises or proteinuria appears, the decline in renal function is usually inevitable. Inflammation is present in the biopsies of patients with chronic graft dysfunction [6] , but little is known about the role of markers of inflammation on graft outcome. The association of inflammation with atherosclerosis and macrovascular disease is well documented in other populations [7, 8] , specifically C-reactive protein (CRP). Cytokines induce production of interleukin-6 (IL-6) from various tissues, including lungs in smokers, and increases downstream mediators such as CRP [9, 10] . Renal transplant recipients, by the process of receiving an allograft, have an additional activation of their inflammation status [11] [12] [13] . We documented recently that the inflammation markers IL-6 and high-sensitivity CRP (hsCRP) were independently associated with cardiovascular events and all-cause mortality in renal transplant recipients [14] . Whether IL-6 predicts graft survival in renal transplant recipients has not yet been documented in a prospective study. The aim of the present study is therefore to investigate the baseline role of inflammatory biomarkers on progressive graft dysfunction and graft failure.
Materials and methods

Study design
The design of the Assessment of Lescol in Renal Transplant (ALERT) trial has been described previously [15] . In short, ALERT was a randomized double-blinded placebo-controlled trial of fluvastatin 40-80 mg in renal transplant patients with follow-up for 5-6 years. Thereafter, participants were offered open-label fluvastatin 80 mg in a 2-year extension study. In all, 2102 renal transplant recipients were included with a mean duration of follow-up for 6.7 years [15, 16] . End points were cardiovascular and renal events, recorded by an independent critical events committee. Recruitment was undertaken from June 1996 to October 1997. Eligible patients were renal transplant recipients 30-75 years old, with stable graft function, transplanted >6 months before enrolment. The patients were recruited to the study at a mean of 5.1 years after transplantation with a stable graft function. Patients were seen 1.5 months after enrolment and at 6 months intervals, recording clinical status and blood biochemistry including lipids, creatinine, creatine kinase and liver enzymes analysed at a central laboratory (CRL, Medinet, Breda, The Netherlands). IL-6 was measured by human IL-6 immunoassay (R&D Systems Inc., Minneapolis, MN) and hsCRP by immunoturbometric analysis (Roche Diagnostics GmbH, Mannheim, Germany). IL-6 and hsCRP were measured at baseline. The study adhered to the International Conference on Harmonization guidelines for Good Clinical Practice and in accordance with the Declaration of Helsinki. All participants provided written informed consent, and the ethics committee at each participating centre approved the trial (no S-02169).
Statistical analysis
In the initial analysis, treatment arm and placebo arm were analysed separately for renal end points. Since the two arms showed no significant heterogeneity in relation between the inflammation markers hsCRP and IL-6, subsequent analyses were performed on the pooled patient population. hsCRP and IL-6 were not normally distributed and logarithmic transformation of these factors was used in the analysis. hsCRP and IL-6 were analysed in separate models due to confounding (not shown) and the close aetiological relationship. Risk factors were evaluated using univariate and multivariate Cox proportional hazard models. Covariates were chosen in a stepwise approach, including covariates with univariate significance and previously reported factors associated with graft outcomes, and then excluding most variables that did not retain statistical significance in the multivariate analysis. SPSS version 17.0 (SPSS Inc., Chicago, IL) was used for statistical analysis.
Results
Baseline characteristics in ALERT and ALERT extension were similar in both treatment arms [15, 16] . Baseline characteristics in relation to renal end points in the placebo group have been reported separately [2] . The present study reports treatment and placebo group together. Baseline characteristics are shown in Table 1 . Mean age at study entry was 50 years, 66% were male and all received cyclosporinebased immunosuppression at entry. The main causes of renal failure leading to transplantation were glomerulonephritis and polycystic kidney disease. Frequencies of graft failure end points are shown in Table 2 .
hsCRP and IL-6 were available in 1910 and 1751 patients, respectively. Mean (SD) and median (interquartile range) values were 3.8 (6.7) mg/L and 1.5 (3.1) mg/L, respectively, for hsCRP, and 2.9 (1.9) pg/mL and 2.4 (2.2) pg/mL for IL-6. The hsCRP and IL-6 cohort had almost identical baseline characteristic as reported earlier [14] , with no differences in proportions with diabetes, coronary heart disease, current smokers or live donor.
Univariate and multivariate hazard ratios (HRs) for the hsCRP and IL-6 cohorts are shown in Tables 3 and 4 . Missing data excluded 450 (21.4%) and 576 (27.4%) patients in the hsCRP and IL-6 multivariate models, Results are expressed as means (SD) and frequencies (percentage of valid) where appropriate.
Inflammation in chronic allograft nephropathy respectively. Both hsCRP and IL-6 were in separate multivariate models significantly associated with the renal end points shown, i.e. death-censored graft loss, graft loss including death and graft loss including death and doubling of serum creatinine. Due to a surprisingly high percentage of current smokers, we performed a separate analysis (not shown) to examine a potential interaction with smoking and inflammation. All interaction covariates were nonsignificant P > 0.20, and the inflammation markers were equally strong in smokers and non-smoker, i.e. no interaction. Excluding smoking as a covariate (not shown) changed the regression coefficients for the inflammation markers <15% and the HRs <5%, indicating no confounding effect.
In multivariate analysis, for death-censored graft loss, the results were similar in the hsCRP and IL-6 cohorts. We found significant negative associations of age and body mass index (BMI). Significant positive associations were seen for current smoking, systolic blood pressure, creatinine, time since last transplantation, two HLA-DR mismatches, previous treatment for rejection and proteinuria.
When including death in the end point, the association of age became significantly positive, diabetes became significant and previous treatment for rejection lost significance. HLA-DR mismatch was significant when including doubling of serum creatinine in the end point. We still found significant negative association of BMI and positive associations of current smoking, systolic blood pressure, creatinine, time since last transplantation and proteinuria.
Discussion
In the present post hoc analysis, we have shown that inflammation, adjusted for traditional risk factors, is associated with death-censored renal graft loss and the composite end points; graft loss or death and graft loss or death or doubling of serum creatinine. To our knowledge, this is the first prospective cohort in renal transplant patients documenting an association of IL-6 with graft loss. HsCRP and IL-6 are close participants in the inflammatory cascade, and the observation that both markers were predictive of outcome parameters, strengthens the perception of inflammation as an important risk factor for graft-related outcomes in renal transplant patients.
The baseline levels of inflammatory markers in our patients seem moderately elevated compared to a nontransplanted background population, as seen in most studies with renal transplant recipients [14] . No universally accepted cut-off values for inflammatory markers in renal transplant recipients exists, but regarding cardiovascular outcomes in the general population CRP < 1 mg/dL confers low risk, CRP 1-3 mg/dL average risk and CRP > 3 mg/dL high risk [17] , and the same cut-off values were described by van Ree et al. [18] predicting a rising creatinine level in renal transplant recipients. This leaves n ¼ 1203 (63%) of our hsCRP cohort with hsCRP > 1 mg/dL in the moderate to high-risk group. IL-6 levels are harder to compare with other studies due to different measurement methodology. A study by Karczewski et al. [19] found significantly higher IL-6 levels in chronic rejection (1.64 AE 0.8 pg/mL) than in patients with stable graft function (0.42 AE 0.3 pg/mL, P < 0.001) or acute rejection (0.93 AE 1.7 pg/dL, P ¼ 0.001).
Our findings supports the concept that inflammation might be a component of the pathogenesis of chronic graft dysfunction and is in line with the report on hsCRP and graft deterioration by van Ree et al. [18] . CRP and IL-6 have been related to renal function in predialytic chronic renal failure [20] . However, the exact pathogenetic role of hsCRP and IL-6 in graft failure is still elusive. Indeed, genetic elevation in CRP was not associated with post-transplant morbidity and mortality [21] , and lowering of hsCRP with statin in dialysis patients did not improve cardiovascular outcome [22] neither did statin treatment improve graft outcome in the ALERT [15] . IL-6 is upstream to CRP in the inflammatory cascade and seems to play an aetiological role in other inflammatory disease states including rheumatoid arthritis [23] , where tocilizumab, a monoclonal antibody against IL-6-receptor, has a proven effect. A murine model of cardiac transplantation demonstrated a tripled survival time of IL-6 deficient grafts [24] , but allogeneic cardiac transplants into IL-6-deficient mice did not show prolonged graft survival indicating that the graft was the relevant source of IL-6. In human heart transplant recipients, IL-6 is associated with low-grade cellular rejection [25] . In renal transplant recipients, elevations in serum and urine IL-6 levels are documented in acute rejection episodes [26] , and increased soluble IL-6 receptor was found in urine 12 and 6 months before late graft failure [27] . A murine model of calcineurin inhibitor nephrotoxicity showed a protective effect of an IL-6-neutralizing antibody [28] , another animal study found a preventive effect of 13-cis-retinoic acid on chronic allograft nephropathy possibly mediated through decreased secretion of inflammatory cytokines including tumour necrosis factor-alpha and IL-6 [29] . Some genetic polymorphism studies in man has shown a protective role on renal graft function of a high IL-6 gene expression in renal transplant recipients, and low IL-6 production donor genotype was associated with increased prevalence of chronic graft dysfunction [30, 31] , whereas other studies failed to show this association [32, 33] . A small retrospective study by Cueto-Manzano et al. [34] found no difference in inflammation markers in patients with or without chronic transplant dysfunction (CTD). A pilot randomized placebo-controlled trial with an inflammation antagonist demonstrated reduced inflammation in maintenance haemodialysis patients [35] . A human randomized trial of IL-6 suppressive therapy might give an answer to whether inflammation is causative in chronic graft dysfunction but is probably still premature awaiting further evidence from mechanistic and correlation studies. Indeed, neutralizing IL-6 antibody treatment in a murine model of acute reperfusion injury was deleterious [36] . Our finding of protective effect of older age of recipient for death-censored graft loss is in line with other studies [18, 37, 38] and might represent higher immunoreactivity in younger subjects. Hypertension, previous rejection and HLA-DR mismatch were independent risk factors in the present study and is in line with current reviews [4, 39] . Creatinine and proteinuria were significant independent risk factors for graft loss as described previously [2, 40] , as was time since transplantation. Creatinine and proteinuria are used as biomarkers of CTD, although they are unspecific of the underlying pathology and not ideal [41] .
Smoking may be a risk factor for reduced patient and graft survival after transplantation [42] . Smoking may per se increase inflammatory markers [9] . Due to a surprisingly high percentage of current smokers, we performed a separate analysis to examine the potential interaction with smoking and inflammation. Although smoking was an independent risk marker, there was no interaction with smoking and inflammation.
A limitation of this study was having only one analysis at baseline for hsCRP and IL-6, and the difference measured between groups is small and of limited prognostic value for individual renal transplant recipients. Our method of choosing covariates increases the possibility of type 1 error and should be regarded as tentative. The strength of the study is the many patients followed for an extended period and an independent adjudication of predefined outcome parameters.
In conclusion, we found that the inflammatory biomarkers hsCRP and IL-6 are significantly associated with graft-related outcomes in renal transplant recipients, independent of the other examined risk factors for graft loss.
